Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 9/20 | 0.40 |
| ▸ | SCN8A | Q9UQD0 | 8/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10129642 | 0.95 | FLT3 (0.47) | TRPV4FLT3SCN10ASCN8ATRPV1 | |
| SCHEMBL10129645 | 0.95 | FLT3 (0.47) | TRPV4FLT3SCN10ASCN8ATRPV1 | |
| SCHEMBL10160202 | 0.87 | MAPK14 (0.41) | FLT3 | |
| SCHEMBL496258 | 0.85 | SCN10A (0.38) | TRPV4SCN10ASCN8ATRPV1 | |
| SCHEMBL496204 | 0.84 | UBE2M (0.43) | TRPV4SCN10ASCN8ATRPV1RXFP1 | |
| Hydrochloric Acid SCHEMBL496005 | 0.84 | SCN8A (0.39) | FLT3SCN10ASCN8ATRPV1RXFP1 | |
| SCHEMBL495747 | 0.83 | SCN10A (0.40) | SCN10ASCN8ATRPV1RXFP1BRD4 | |
| Hydrochloric Acid SCHEMBL495631 | 0.83 | SCN8A (0.40) | FLT3SCN10ASCN8ATRPV1RXFP1 | |
| SCHEMBL496549 | 0.82 | SCN10A (0.41) | SCN10ASCN8ATRPV1RXFP1 | |
| SCHEMBL10160985 | 0.82 | FLT3 (0.43) | FLT3MAPK1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1955697-B1 | 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER | ASTELLAS PHARMA INC (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-8106190-B2 | 2-aminobenzamide derivatives | ASTELLAS PHARMA INC. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | TRPV1, TRPV2, TRPV5 | TRPV4 6/4885FLT3 4496/4885SCN10A 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.